Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets

Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2020-02, Vol.63 (3), p.884-904
Main Authors: Skok, Žiga, Zidar, Nace, Kikelj, Danijel, Ilaš, Janez
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a460t-94665acbbdc5f8787ea1a82149e826d4f4d4519903cab9dd9993aeab686fc3473
cites cdi_FETCH-LOGICAL-a460t-94665acbbdc5f8787ea1a82149e826d4f4d4519903cab9dd9993aeab686fc3473
container_end_page 904
container_issue 3
container_start_page 884
container_title Journal of medicinal chemistry
container_volume 63
creator Skok, Žiga
Zidar, Nace
Kikelj, Danijel
Ilaš, Janez
description Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic point of view. There are various different options for the preparation of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated anticancer targets. In this Perspective, we discuss the scientific background behind targeting topoisomerase II together with a number of other targets important in cancer therapy, review the present status, and discuss further options in the field.
doi_str_mv 10.1021/acs.jmedchem.9b00726
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2302473557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2302473557</sourcerecordid><originalsourceid>FETCH-LOGICAL-a460t-94665acbbdc5f8787ea1a82149e826d4f4d4519903cab9dd9993aeab686fc3473</originalsourceid><addsrcrecordid>eNp9kE1PwkAQhjdGI4j-A2P26KW4X126RwIqJAQSg-dmup1KSdvF3fbgv7cIevQ0h3nedzIPIfecjTkT_AlsGO9rzO0O67HJGJsIfUGGPBYsUglTl2TImBCR0EIOyE0Ie8aY5EJek4HksRFa6SFZzzuo6LLZlVnZOh-oK-iiq6Gh8_WUbt3BlcHV6CEgXS4pNDndtDv0dAaNRR-9YQUt5nQL_gPbcEuuCqgC3p3niLy_PG9ni2i1eV3OpqsIlGZtZJTWMdgsy21cJJNkgsAhEVwZTITOVaFyFXNjmLSQmTw3xkhAyHSiCyvVRI7I46n34N1nh6FN6zJYrCpo0HUhFZKJHovjI6pOqPUuBI9FevBlDf4r5Sw9mkx7k-mvyfRsso89nC90Wb_7C_2q6wF2An7irvNN__D_nd-wtIG2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2302473557</pqid></control><display><type>article</type><title>Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Skok, Žiga ; Zidar, Nace ; Kikelj, Danijel ; Ilaš, Janez</creator><creatorcontrib>Skok, Žiga ; Zidar, Nace ; Kikelj, Danijel ; Ilaš, Janez</creatorcontrib><description>Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic point of view. There are various different options for the preparation of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated anticancer targets. In this Perspective, we discuss the scientific background behind targeting topoisomerase II together with a number of other targets important in cancer therapy, review the present status, and discuss further options in the field.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.9b00726</identifier><identifier>PMID: 31592646</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>Journal of medicinal chemistry, 2020-02, Vol.63 (3), p.884-904</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a460t-94665acbbdc5f8787ea1a82149e826d4f4d4519903cab9dd9993aeab686fc3473</citedby><cites>FETCH-LOGICAL-a460t-94665acbbdc5f8787ea1a82149e826d4f4d4519903cab9dd9993aeab686fc3473</cites><orcidid>0000-0002-0124-0474 ; 0000-0003-1905-0158</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31592646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Skok, Žiga</creatorcontrib><creatorcontrib>Zidar, Nace</creatorcontrib><creatorcontrib>Kikelj, Danijel</creatorcontrib><creatorcontrib>Ilaš, Janez</creatorcontrib><title>Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic point of view. There are various different options for the preparation of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated anticancer targets. In this Perspective, we discuss the scientific background behind targeting topoisomerase II together with a number of other targets important in cancer therapy, review the present status, and discuss further options in the field.</description><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PwkAQhjdGI4j-A2P26KW4X126RwIqJAQSg-dmup1KSdvF3fbgv7cIevQ0h3nedzIPIfecjTkT_AlsGO9rzO0O67HJGJsIfUGGPBYsUglTl2TImBCR0EIOyE0Ie8aY5EJek4HksRFa6SFZzzuo6LLZlVnZOh-oK-iiq6Gh8_WUbt3BlcHV6CEgXS4pNDndtDv0dAaNRR-9YQUt5nQL_gPbcEuuCqgC3p3niLy_PG9ni2i1eV3OpqsIlGZtZJTWMdgsy21cJJNkgsAhEVwZTITOVaFyFXNjmLSQmTw3xkhAyHSiCyvVRI7I46n34N1nh6FN6zJYrCpo0HUhFZKJHovjI6pOqPUuBI9FevBlDf4r5Sw9mkx7k-mvyfRsso89nC90Wb_7C_2q6wF2An7irvNN__D_nd-wtIG2</recordid><startdate>20200213</startdate><enddate>20200213</enddate><creator>Skok, Žiga</creator><creator>Zidar, Nace</creator><creator>Kikelj, Danijel</creator><creator>Ilaš, Janez</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0124-0474</orcidid><orcidid>https://orcid.org/0000-0003-1905-0158</orcidid></search><sort><creationdate>20200213</creationdate><title>Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets</title><author>Skok, Žiga ; Zidar, Nace ; Kikelj, Danijel ; Ilaš, Janez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a460t-94665acbbdc5f8787ea1a82149e826d4f4d4519903cab9dd9993aeab686fc3473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skok, Žiga</creatorcontrib><creatorcontrib>Zidar, Nace</creatorcontrib><creatorcontrib>Kikelj, Danijel</creatorcontrib><creatorcontrib>Ilaš, Janez</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skok, Žiga</au><au>Zidar, Nace</au><au>Kikelj, Danijel</au><au>Ilaš, Janez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2020-02-13</date><risdate>2020</risdate><volume>63</volume><issue>3</issue><spage>884</spage><epage>904</epage><pages>884-904</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic point of view. There are various different options for the preparation of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated anticancer targets. In this Perspective, we discuss the scientific background behind targeting topoisomerase II together with a number of other targets important in cancer therapy, review the present status, and discuss further options in the field.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>31592646</pmid><doi>10.1021/acs.jmedchem.9b00726</doi><tpages>21</tpages><orcidid>https://orcid.org/0000-0002-0124-0474</orcidid><orcidid>https://orcid.org/0000-0003-1905-0158</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2020-02, Vol.63 (3), p.884-904
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_2302473557
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
title Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20Inhibitors%20of%20Human%20DNA%20Topoisomerase%20II%20and%20Other%20Cancer-Related%20Targets&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Skok,%20Z%CC%8Ciga&rft.date=2020-02-13&rft.volume=63&rft.issue=3&rft.spage=884&rft.epage=904&rft.pages=884-904&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.9b00726&rft_dat=%3Cproquest_cross%3E2302473557%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a460t-94665acbbdc5f8787ea1a82149e826d4f4d4519903cab9dd9993aeab686fc3473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2302473557&rft_id=info:pmid/31592646&rfr_iscdi=true